Hepatic and hippocampal cytochrome P450 enzyme overexpression during spontaneous recurrent seizures

被引:22
|
作者
Runtz, Leonie [1 ]
Girard, Benoit [2 ]
Toussenot, Marion [1 ]
Espallergues, Julie [3 ]
De Maudave, Alexis Fayd'Herbe [1 ]
Milman, Alexandre [4 ]
deBock, Frederic [1 ]
Ghosh, Chaitali [5 ]
Guerineau, Nathalie C. [4 ]
Pascussi, Jean-Marc [6 ]
Bertaso, Federica [2 ]
Marchi, Nicola [1 ]
机构
[1] CNRS, Inst Funct Genom, Lab Cerebrovasc Mech Brain Disorders, UMR 5203,U1191,INSERM, Montpellier, France
[2] CNRS, Inst Funct Genom, Lab Pathophysiol Synapt Transmiss, UMR 5203,U1191,INSERM, Montpellier, France
[3] Histalim, Montpellier, France
[4] CNRS, Inst Funct Genom, Ion Channels Neuronal Excitabil & Dis, UMR 5203,U1191,INSERM, Montpellier, France
[5] Cleveland Clin, Cerebrovasc Res, Cleveland, OH 44106 USA
[6] CNRS, Lab Self Renewal & Differentiat Epithelia, Inst Funct Genom, UMR 5203,U1191,INSERM, Montpellier, France
关键词
inflammation; drug metabolism; epilepsy; liver; P450; BLOOD-BRAIN-BARRIER; XENOBIOTIC RECEPTORS; ABC TRANSPORTERS; MOUSE MODEL; EXPRESSION; NUCLEAR; INDUCTION; CORTISOL; STRESS; P450;
D O I
10.1111/epi.13942
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveAvailable evidence points to a role of cytochrome P450 (Cyp) drug biotransformation enzymes in central nervous system diseases, including epilepsy. Deviations in drug pharmacokinetic profiles may impact therapeutic outcomes. Here, we ask whether spontaneous recurrent seizure (SRS) activity is sufficient to modulate the expression of major Cyp enzymes in the liver and brain. MethodsUnilateral intrahippocampal (IH) kainic acid (KA) injections were used to elicit nonconvulsive status epilepticus (SE), epileptogenesis, and SRS, as monitored by video-electroencephalography. Intraperitoneal (IP) KA injection was used to trigger generalized tonic-clonic SE. KA-injected mice and sham controls were sacrificed at 24-72 hours and 1 week post-SE (IH or IP KA), and during the chronic stage (SRS; 6 weeks post-IH KA). Liver and brain tissues were processed for histology, real-time quantitative polymerase chain reaction, Western blot, or microsomal enzymatic assay. Cyp2e1, Cyp3a13, glial fibrillary acidic protein (GFAP), IBA1, xenobiotic nuclear receptors nr1i2 (PXR), nr1i3 (CAR) and nr3c1 (glucocorticoid receptor [GR]) expression was examined. Serum samples were obtained to assay corticosterone levels, a GR activator. ResultsA significant increase of Cyp3a13 and Cyp2e1 transcript level and protein expression was found in the liver and hippocampi during SRS, as compared to control mice. In the ipsilateral hippocampus, Cyp2e1 and Cyp3a protein upregulation during SRS positively correlated to GFAP expression. GFAP(+), and not IBA1(+), cells colocalized with Cyp2e1 or Cyp3a expression. In the liver, a trend increase in Cyp3a microsomal activity was found during SRS as compared to control mice. The transcript levels of the Cyp upstream regulators GR, xenobiotic nr1i2, and nr1i3 receptors were unchanged at SRS. Corticosterone levels, a GR ligand, were increased in the blood post-SE. SignificanceSRS modifies Cyp expression in the liver and the hippocampus. Nuclear receptors or inflammatory pathways are candidate mechanisms of Cyp regulation during seizures.
引用
收藏
页码:123 / 134
页数:12
相关论文
共 50 条
  • [21] Consequences of Phenytoin Exposure on Hepatic Cytochrome P450 Expression during Postnatal Liver Maturation in Mice
    Piekos, Stephanie C.
    Chen, Liming
    Wang, Pengcheng
    Shi, Jian
    Yaqoob, Sharon
    Zhu, Hao-Jie
    Ma, Xiaochao
    Zhong, Xiao-bo
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (08) : 1241 - 1250
  • [22] Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase
    Guengerich, F. Peter
    Martin, Martha V.
    Sohl, Christal D.
    Cheng, Qian
    NATURE PROTOCOLS, 2009, 4 (09) : 1245 - 1251
  • [23] Regulation of hepatic cytochrome P450 2C11 by glucocorticoids
    Iber, H
    Chen, Q
    Sewer, M
    Morgan, ET
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 345 (02) : 305 - 310
  • [24] Listeriosis downregulates hepatic cytochrome P450 enzymes in sublethal murine infection
    Kummer, Anne
    Nishanth, Gopala
    Koschel, Josephin
    Klawonn, Frank
    Schlueter, Dirk
    Jaensch, Lothar
    PROTEOMICS CLINICAL APPLICATIONS, 2016, 10 (9-10) : 1025 - 1035
  • [25] Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes
    Krogstad, Veronica
    Peric, Alexandra
    Robertsen, Ida
    Kringen, Marianne K.
    Vistnes, Maria
    Hjelmesaeth, Joran
    Sandbu, Rune
    Johnson, Line Kristin
    Angeles, Philip Carlo
    Jansson-Lofmark, Rasmus
    Karlsson, Cecilia
    Andersson, Shalini
    Asberg, Anders
    Andersson, Tommy B.
    Christensen, Hege
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (01) : 432 - 437
  • [26] Decrease in hepatic cytochrome P450 after interleukin-2 Immunotherapy
    Elkahwaji, J
    Robin, MA
    Berson, A
    Tinel, M
    Lettéron, P
    Labbe, G
    Beaune, P
    Elias, D
    Rougier, P
    Escudier, B
    Duvillard, P
    Pessayre, D
    BIOCHEMICAL PHARMACOLOGY, 1999, 57 (08) : 951 - 954
  • [27] Effect of Hemodialysis on Hepatic Cytochrome P450 Functional Expression
    Michaud, Josee
    Nolin, Thomas D.
    Naud, Judith
    Dani, Melina
    Lafrance, Jean-Philippe
    Leblond, Francois A.
    Himmelfarb, Jonathan
    Pichette, Vincent
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 108 (02) : 157 - 163
  • [28] Practical Application of Cytochrome P450
    Sakaki, Toshiyuki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2012, 35 (06) : 844 - 849
  • [29] Molecular imaging of cytochrome P450 activity in mice
    Roncoroni, Chiara
    Rizzi, Nicoletta
    Brunialti, Electra
    Cali, James J.
    Klaubert, Dieter H.
    Maggi, Adriana
    Ciana, Paolo
    PHARMACOLOGICAL RESEARCH, 2012, 65 (05) : 531 - 536
  • [30] Unlocking the Clinical Significance of Cytochrome P450 Enzymes
    Hadia, Rajesh
    Singh, Vishal
    Solanki, Nidhi
    Sharma, Shiwanand
    Saggu, Varunsingh
    Sajan, Cyril
    Trivedi, Rahul
    Kardani, Sunil
    Baile, Sunil
    Rajput, Hemraj Singh
    Maheshwari, Rajesh
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2024, 14 (01) : 30 - 38